Antiviral Small Molecule Drug Discovery and Development Programs


arenavirus Arenaviruses are transmitted to humans through infected rodents and contaminated materials. At least seven arenavirus species including Lassa Virus (LASV) can cause severe viral hemorrhagic fevers. Each year over 300,000 infections and 5000 deaths are associated with LASV alone. We are developing a lead series of novel broad-spectrum arenavirus cell entry inhibitors in association with the National Institute for Allergy and Infectious Disease (NIAID) (Grant R44AI112097).


ebola Ebola viruses are endemic to regions of Africa and may be spread from human to human through transmission of bodily fluids. As witnessed in the 2014-2015 West African outbreak, which has claimed over 11,000 lives, Ebola virus infection in humans is associated with severe hemorrhagic fever and high risk of mortality. Arisan is developing novel Ebola virus entry inhibitors in association with NIAID (GRANT R43AI118207).


influenza Influenza A viruses are a rapidly evolving and highly diverse group of viruses associated with mild to severe disease symptoms. Annual seasonal outbreaks, typically spread through human to human contact, result in ~ 3-5 million cases of severe illness globally. More highly pathogenic strains of influenza, including H5N1 and H7N9 which remain primarily restricted to birds, exhibit lethality in ~ 30-50% of infected individuals. These viruses may evolve to spread through casual human contact. Arisan received support from NIAID (Grant R43AI106266) to develop novel broad-spectrum influenza A therapeutics.


dengue Dengue viruses are carried by several species of mosquitos and found geographically in regions containing approximately 40% of the human global population. The virus has five different types. Infection with one type usually gives immunity to that type while subsequent infection with a different type increases the risk of complication and severity including dengue hemorrhagic fever. With NIAID support (Grant R43AI104106) Arisan is identifying novel inhibitors for the treatment of dengue virus infection.

Creative Commons Attribution: